CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin
Mine, Naoki, Yamamoto, Sayaka, Saito, Naoya, Yamazaki, Satoshi, Suda, Chikako, Ishigaki, Machiyo, Kufe, Donald W, Von Hoff, Daniel D, Kawabe, Takumi
Published in Molecular cancer therapeutics (01.10.2011)
Published in Molecular cancer therapeutics (01.10.2011)
Get full text
Journal Article
Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site
Matsumoto, Yuki, Shindo, Yosuke, Takakusagi, Yoichi, Takakusagi, Kaori, Tsukuda, Senko, Kusayanagi, Tomoe, Sato, Hitoshi, Kawabe, Takumi, Sugawara, Fumio, Sakaguchi, Kengo
Published in Bioorganic & medicinal chemistry (01.12.2011)
Published in Bioorganic & medicinal chemistry (01.12.2011)
Get full text
Journal Article
Cdc25C interacts with PCNA at G2/M transition
Kawabe, Takumi, Suganuma, Masashi, Ando, Tomoaki, Kimura, Mayumi, Hori, Haruna, Okamoto, Takashi
Published in Oncogene (07.03.2002)
Published in Oncogene (07.03.2002)
Get full text
Journal Article
NF-κB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2
YANG, J.-P, HORI, M, TAKAHASHI, N, KAWABE, T, KATO, H, OKAMOTO, T
Published in Oncogene (16.09.1999)
Published in Oncogene (16.09.1999)
Get full text
Journal Article
Boromycin Abrogates Bleomycin-induced G2 Checkpoint
ARAI, MASAYOSHI, KOIZUMI, YUKIO, SATO, HITOSHI, KAWABE, TAKUMI, SUGANUMA, MASASHI, KOBAYASHI, HIDETAKA, TOMODA, HIROSHI, OMURA, SATOSHI
Published in Journal of antibiotics (2004)
Published in Journal of antibiotics (2004)
Get full text
Journal Article
Identification of U83836E as a γ-glutamylcyclotransferase inhibitor that suppresses MCF7 breast cancer xenograft growth
Ii, Hiromi, Nohara, Yukie, Yoshiya, Taku, Masuda, Shun, Tsuda, Shugo, Oishi, Shinya, Friedman, Jonathan, Kawabe, Takumi, Nakata, Susumu
Published in Biochemical and biophysical research communications (16.04.2021)
Published in Biochemical and biophysical research communications (16.04.2021)
Get full text
Journal Article
Abstract CT228: Phase Ib clinical study of CBP501, cisplatin and nivolumab administered every 3 weeks in patients with advanced refractory tumors. Dose escalation cohort
Matrana, Marc, Tsai, Frank, Satti, Suma, Cleary, James, Estes, Jacob, Do, Khanh, Kolmakov, Valentin, Kawabe, Takumi, Shapiro, Geoffrey I.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
Sakakibara, Keiichi, Saito, Naoya, Sato, Takuji, Suzuki, Atsushi, Hasegawa, Yoko, Friedman, Jonathan M., Kufe, Donald W., VonHoff, Daniel D., Iwami, Tadahiko, Kawabe, Takumi
Published in Blood (06.10.2011)
Published in Blood (06.10.2011)
Get full text
Journal Article
IDO/TDO INHIBITOR
ASAI AKIYOSHI, SATO TAKUJI, TAKIGAWA OSAMU, OGO NAOHISA, MURAOKA DAISUKE, MURAKAMI HISASHI, KAWABE TAKUMI
Year of Publication 23.01.2024
Get full text
Year of Publication 23.01.2024
Patent
CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding
Saito, Naoya, Mine, Naoki, Kufe, Donald W, Von Hoff, Daniel D, Kawabe, Takumi
Published in Oncotarget (26.09.2017)
Published in Oncotarget (26.09.2017)
Get full text
Journal Article
Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts
Matrana, Marc Ryan, Tsai, Frank, Cleary, James M., Satti, Suma, Borazanci, Erkut, Estes, Jacob, Moser, Justin, Do, Khanh Tu, Du, Lingling, Sharma, Sunil, Khemka, Vivek, Kolmakov, Valentin, Kawabe, Takumi, Shapiro, Geoffrey
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice
Sakakibara, Keiichi, Sato, Takuji, Kufe, Donald W, VonHoff, Daniel D, Kawabe, Takumi
Published in Oncotarget (03.10.2017)
Published in Oncotarget (03.10.2017)
Get full text
Journal Article
IDO/TDO INHIBITOR
ASAI AKIYOSHI, SATO TAKUJI, TAKIGAWA OSAMU, OGO NAOHISA, MURAOKA DAISUKE, KAWABE TAKUMI
Year of Publication 20.06.2023
Get full text
Year of Publication 20.06.2023
Patent
CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway
Saito, Naoya, Sakakibara, Keiichi, Sato, Takuji, Friedman, Jonathan M, Kufe, Donald W, VonHoff, Daniel D, Kawabe, Takumi
Published in Molecular cancer therapeutics (01.12.2014)
Published in Molecular cancer therapeutics (01.12.2014)
Get full text
Journal Article
Abstract C106: CBP501 potentiates the appearance of cisplatin-induced indicators of immunogenic cell death and promotes anti-tumor effects in an immuno-competent mouse model
Sakakibara, Keiichi, Sato, Takuji, Kufe, Donald W., Von Hoff, Daniel D., Kawabe, Takumi
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
Abstract A110: CBP501 suppresses cell migration, invasion and epithelial-mesenchymal transition (EMT) in non-small cell lung carcinoma
Saito, Naoya, Mine, Naoki, Kufe, Donald W., Von Hoff, Daniel D., Kawabe, Takumi
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article